Day One Biopharmaceuticals (DAWN) has issued an update.
Day One Biopharmaceuticals, Inc. has entered into a securities purchase agreement with select investors, selling over 10 million shares and approximately 1.5 million pre-funded warrants in a private placement set to close on August 1, 2024. This move is expected to generate $175 million in gross proceeds, earmarked for expanding commercial capabilities, R&D, potential acquisitions, and general corporate purposes. The terms also include registration rights for the resale of the shares and warrant shares, demonstrating the company’s commitment to investor relations and compliance with securities regulations.
See more data about DAWN stock on TipRanks’ Stock Analysis page.
